Navigation Links
Generex Provides Update on Spinout of Antigen Express
Date:9/15/2011

-looking statement.  Risks and uncertainties relating to the proposed activities and transactions discussed in this press release include the risks that: (1) No transaction will be effected between Antigen and the prospective merger partner; (2) Antigen will not be successful in raising sufficient capital to carry out its business plans; (3) Antigen will not meet the standards for listing its common stock on a national stock exchange; (4) the anticipated benefits of the contemplated merger will not be realized; and (5) Generex will be required to cede more ownership of Antigen to new investors than currently planned.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


'/>"/>
SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Announces $3.0 Million Capital Investment
10. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
11. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 “This kit has an improved ... from 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin ... benefit to plant owners and USDA-GIPSA inspection agencies that have ... Testing can take place in a matter of minutes with ... plant test the feed and grain before accepting it, but ...
(Date:8/28/2014)... PA (PRWEB) August 28, 2014 The ... create a culture that will allow individuals to perform ... becoming increasingly important for employers looking to compete in ... industries are embracing this trend, as the sector increasingly ... of a company, which will have real results on ...
(Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Earlier this ... University in partnership with the U.S. Air Force ... biofuel. The results indicated that this type of fuel ... feedstock and will be important to America’s Eco friendly ... now has a mandate to become independent of foreign ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... Therapeutics Corporation,announced today that it has entered into ... SHPGY, TSX: SHQ), to jointly develop AT-1001,Alba,s lead ... Shire will receive rights to commercialize all forms ... Alba will retain all rights,to commercialize AT-1001 in ...
... Dec. 14 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ... promoted B. Lynne Parshall, J.D. to Chief Operating ... Chief Financial,Officer, and is a Director of the ... reflects the scope,of Lynne,s responsibilities at Isis," commented ...
... PHILADELPHIA, Dec. 14 FMC Corporation (NYSE:,FMC) ... announced the companies,have entered into a worldwide ... a novel capsule technology developed by FMC. ... strengthen,the product life-cycle management of Pronova BioPharma,s ...
Cached Biology Technology:Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001 2Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001 3Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 2Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 3FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 2FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 3FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 4
(Date:8/28/2014)... MARC (Maximizing Access to Research Careers) Program has ... College of Sports Medicine,s Conference on Integrative Physiology ... Florida. These awards are meant to promote ... from underrepresented groups into the mainstream of the ... of young scientists at the American College of ...
(Date:8/28/2014)... German . Cars, ... help of sophisticated assembly lines. Mobile assembly carriers, on to ... these assembly lines. In the case of a car body, ... in a precise spatial and chronological sequence, resulting in a ... creation of such an assembly line at molecular level has ...
(Date:8/28/2014)... assigned a number of 435-million-year-old fossils to a ... in shallow marine habitats and were far less ... , Before they sank to the bottom ... some 435 million years ago, these arthropods preyed ... although they were not exactly inconspicuous, possessing a ...
Breaking Biology News(10 mins):Nanoscale assembly line 2Nanoscale assembly line 3Paleontology: Oldest representative of a weird arthropod group 2
... When you think you see a face in the clouds or ... be upside down. It turns out the answer to this ... to. Using tests of visual perception and functional magnetic resonance ... Ontario,s world-renowned Centre for Brain & Mind recently measured activity in ...
... Mention vitamin D-fortified foods and most people think ... vitamin since the 1930s. A new episode in the ... series says that vitamin D-fortified bread could join milk ... is difficult to get naturally in foods. ...
... Minnesota,s College of Biological Sciences, has been awarded a five-year, ... direct a large-scale research effort to study a human antiviral ... The goal of the study will be to produce ... how it interacts with other proteins in human cells and ...
Cached Biology News:U of M scientist gets 5-year, $10 million grant to direct innovative HIV research program 2
... Recognizes an epitope located in ... isotype IV. No reactivity with ... ascites fluid synthetic peptide corresponding ... β-tubulin isotype IV, conjugated to ...
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
... catalyzes the joining of two strands of ... groups of adjacent nucleotides in either a ... has also been shown to catalyze the ... or RNA strand in a duplex molecule ...
Biology Products: